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INTRODUCTION
Postmenopausal bleeding (PMB) is vaginal bleeding in postmeno-
pausal women, which is different from that we expect in women who use 
sequential hormonal substitution therapy (1).
Every postmenopausal bleeding, whether it is spot-like or heavy, requires 
further evaluation of these patients. It can be caused by benign changes in 
endometrial, which can be diffuse (hyperplasia and atrophy), focal (endo-
metrial polyp), and malignant (2-4). Endometrial cancer represents 6% of 
all female cancers. In the U.S., Canada, and Western Europe endometrial 
cancer is diagnosed in 8% to 12 % of all malignancies of women while in 
Eastern Europe it is diagnosed in 2% to 4 % (5).
Cancer of uterine corpus is the sixth among cancers in women in the 
region of Vojvodina (6). Incidence of endometrial cancer depends on age. 
In women aged 40 years endometrial cancer occurs in 12/100 000, and 
in women aged 60 years it is 84/100 000 (7). Only 4% of these patients 
with endometrial cancer are women younger than 40 years, and 25 % are 
women in premenopausal period. Approximately 75% of endometrial can-
cers occur in postmenopausal period, and 50 % of these are associated 
with risk factors (7). Numerous multicentre epidemiological studies point-
ed to their existence and a high correlation between endometrial cancer 
and risk factors. There are endogenous and exogenous risk factors. Ninety 
percent of patients with endometrial cancer visit a gynecologist because 
of vaginal bleeding in the form of menometrorrhagia in perimenopause 
or menstruation-like bleeding in postmenopause (8). Possibility that the 
postmenopausal bleeding is caused by endometrial cancer depends on 
patients age and it is diagnosed at approximately 9% of women 50 years 
old, 16% women 60 years old, 28% those of 70 years, and 60% at women 
of 80 years (9). Thus, it is necessary examine every PMB and find out the 
cause of it. Basic diagnostic approach considers (9):
–  Anamnesis and gynecological examination
–  Transvaginal ultrasound
–  Methods of sampling endometrial tissue for histopathological analysis
–  Additional diagnostic methods
MATERIAL AND METHODS
Our retrospective study included 122 patients in postmenopausal period 
that came to a gynecologist because of bleeding from uterus. We used 
data of patients who had their last period at least one year ago.
Basic clinical data were taken from the hospital records of the Oncology 
Institute of Vojvodina and Clinic for Gynecology and Obstetrics, Clinical 
Center of Vojvodina. After gynecological and examination by transvaginal 
ultrasound, the patients underwent fractionate explorative curettage in 
local or short-term intravenous anesthesia.
Histopathological analysis of the samples was done in the Department for 
pathology and cytological diagnostics, Oncology Institute of Vojvodina, 
and Center for pathology and histology, Clinical Center of Vojvodina. 
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SUMMARY
Background: Incidence of endometrial carcinoma in Vojvodina is 15-20/100 000. In 75% cases, endometrial carci-
noma is diagnosed in postmenopausal period. In 90 % of patients, the first clinical sign is postmenopausal bleeding. 
The aim of the study was to investigate clinical and histopathological characteristics in patients with postmenopausal 
bleeding.
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cal examination and vaginal ultrasound. We obtained materials for histopathological analysis by fractionate explorative 
curettage. Once we had definitive histopathological findings, we divided patients in two groups A (endometrial carci-
noma) and B (benign changes).
Results: We confirmed significant statistical differences between examined group A and B, including age (64.49 
compared with 58.81 years), postmenopausal period (13.67 instead 9.11 years), and length of uterine corpus (6.41 
instead 5.25 cm).
Conclusion: Elderly women with longer postmenopausal interval and postmenopausal bleeding had increased risk for 
endometrial carcinoma. Measurement of endometrial thickness by transvaginal ultrasound appeared to be insufficient 
parameter for differentiating the benign from the malignant changes of endometrium. Patients with endometrial car-
cinoma had significantly longer corpus of uterus comparing to patients with benign changes. Body mass index was 
not found to be significant risk factor in development of endometrial carcinoma in the examined groups. Obesity was 
diagnosed in both groups, suggesting that increased body mass index is a risk factor for development of pathological 
changes in endometrium, which could lead to postmenopausal bleeding.
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Based on histopathological findings the patients were classified in two 
groups:
–  Group A - patients with endometrial cancer
–  Group B - absence of malignity, benign changes (hyperplasia of endo-
metrium, myoma, endometrial polyp, atrophic endometrium).
Statistical processing
During statistical data processing, we calculated descriptive statistics – 
frequency, percent, mean values, and standard deviation. We presented 
our results using column charts, pie, histograms, and box-whiskers 
diagrams. We used t-test and analysis of variants for comparisons, to 
establish whether there was statistical significant difference between 
mean values numerical features. Significant differences (p< 0.05) were 
marked with *, and highly significant differences (p< 0.01) with **.
RESULTS
The study results were obtained after the analysis and statistical process-
ing of hospital records of 122 patients. All patients were examined in the 
Oncology Institute of Vojvodina and Clinic for Gynecology and Obstetrics, 
Clinical Center of Vojvodina.
Average age of patients was 61.56 years. The youngest had 46 and the 
oldest had 88 years. The average weight and height of women was 79.20 
kg and 162 cm, respectively. Average BMI was 30.23, which indicated 
obesity in the examined group with minimal BMI 18.03 and maximal 
44.08. Average age of menarche was 13.56 years and average regular 
menstrual cycle was 28.76 days. Transvaginal ultrasound examination 
showed that average length of uterus was 5.81 cm (minimal length 3 
cm and maximal length 12 cm). Average thickness of endometrium was 
12.65 mm (minimal measured thickness was 4 mm and maximal was 
50 mm). The average appearance of menopause was at 50.22 year and 
mean duration of menopause was 11.32 years (Table 1).
Numerical variables Number of 
patients
Minimum Maximum Mean value Standard 
deviation
Age of patient 122 46  88 61.56  8.83
Weight 122 45.00 120.00 79.20 13.86
Height 122  1.46   1.85  1.62  0.06
BMI 122 18.03  44.08 30.23  5.00
Menarche 122 10  17 13.56  1.53
Regularity of menstrual cycle 122 21  50 28.76  2.51
Length of corpus of uterus (cm) 122  3.00  12.00  5.81  1.73
Thickness of endometrium (mm) 122  4.00  50.00 12.66   6.95
Menopause 122 36  60 50.22  4.06
Years in menopause 122  0.5  48.00 11.32   9.66
Patients were divided in two groups based on histopathological findings 
obtained after fractionate explorative curettage.
Group A - patients with endometrial cancer
Group B - absence of malignity, benign changes (hyperplasia of endome-
trium, myoma, endometrial polyp, atrophic endometrium).
In A group, there were 59 patients and in group B 63 patients (Table 2).
Table 2. Patients
Group Patients (No.) Percent (%)
Malignant (A) 59 48.4
Benign (B) 63 51.6
Total 122 100.0
Endometroid type of adenocarcinoma was most frequently diagnosed in 
group A (78% patients). Adenoacanthoma was diagnosed in 3.4% of patients, 
as well as adenosquamous type. Clear cell tumor was detected in 6.7% cases 
and seropapillary type of adenocarcinoma was diagnosed in 6.8%. Mucinous 
type was diagnosed in 1.7% of patients in group A (Figure 1).
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Figure 1. Histopathological findings in group A
According to differentiation degree of endometrial cancer, 35.6% of 
patients were well differentiated (G1), 45.8% were moderately differenti-
ated (G2), and in 18.6% it was a poor differentiated tumor (Figure 2).
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Figure 2. Differentiation degree of endometrial cancer tumor cells
Average age of patients with endometrial cancer was 64.49 years. The 
youngest patient had 50 years, and the oldest had 88 years. Average 
value of BMI was 30.55. Menarche averagely appeared at 13.51 year, and 
average regular cycle was 29.1 days. Transvaginal ultrasound examina-
tion showed that the average length of uterus corpus was 6.41 cm, and 
endometrial thickness was 13.36 mm (Table 3).
Histopathological findings in the B group showed that it is endometrial 
hyperplasia in 52.4%, in 25.4% it was diagnosed polyp, and in 19% atro-
phic endometrium, while submucous myoma was diagnosed in 3.2%. 
Submucous myoma was confirmed after hysterectomy (Figure 3).
Table 1. Basic characteristics of patients for numeric variables7
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Figure 3. Histopathological findings in the B group
Average age of patients in the B group with benign changes was 58.81 
years, the youngest was 46, and the oldest was 79 years old. Average 
weight  was  78.73  kg,  and  height  162  cm.  Average  BMI  was  29.92. 
Average time of menarche appearing in examined benign group was 13.6 
year, and average regular cycle was 28.44 days. Transvaginal ultrasound 
examination measured the average length of uterus corpus was 5.25 
cm, with minimal length 3 cm and maximal 10 cm. Average endometrial 
thickness was 11.99 mm (Table 3). Menopause appeared averagely in 
50 year of life, and average duration of postmenopausal period was 9.11 
years (Table 4).
We used t-test for equality of mean for testing of statistical significance 
between numerical variables of examined groups. Statistical significance 
was confirmed for age, length of uterus, and duration of menopause in 
both groups. Group of patients with malignant changes of endometrium 
was, on average, older (64.49 compared with 58.81 years); corpus of 
uterus was longer (6.41 compared with 5.25 cm), and their menopause 
lasted longer (13.67 compared to 9.11 years) (Table 5, Figures 4, 5 and 
6). Other parameters had no significant statistical difference. 
DISCUSSION
Endometrial cancer is most often diagnosed tumor of female genital tract 
in developed countries (9). In developing countries as well as it is in our 
country there is rising tendency for incidence of this cancer (10, 11).
In 75% of cases, endometrial cancer appears in women in menopause 
so we can talk about cancer of older population. Incidence of endometrial 
cancer rises from 2/100 000 of women under 40 years old to 40-50/100 
000 of women in sixth, seventh, and eight decade of life (12).
Average age of women with endometrial cancer in our study was 
64.49 years and that is a statistically significant difference from women 
with benign changes of endometrium with average age of 58.8 years. 
However, 25% of endometrial cancer appears in premenopausal period 
while 5% of diagnoses are established among women younger than 40 
years (13). The risk for developing endometrial cancer is associated 
Table 3. Basic characteristics of patients with malignant changes (Group A)
Numerical variables Number  
of patients
Minimum Maximum Mean 
value
Standard 
deviation
Age of patient 59 50 88 64.49 8.80
Weight 59 52.00 120.00 79.71 12.90
Height 59 1.46 1.72 1.61 0.06
BMI 59 20.31 44.08 30.55 4.69
Menarche 59 10 17 13.51 1.60
Regularity of menstrual cycle 59 25 50 29.10 3.30
Length of corpus of uterus (cm) 59 4.00 12.00 6.41 1.91
Thickness of endometrium (mm) 59 5.00 50.00 13.36 7.50
Menopause 59 40 60 50.46 4.17
Years in menopause 59 0.5 48.00 13.67 10.15
Table 4. Basic characteristics of patients without malignant changes (Group B)
Numerical variables Number 
of patients
Minimum Maximum Mean 
value
Standard 
deviation
Age of patient 63 46 79 58.81 7.99
Weight 63 45.00 120.00 78.73 14.80
Height 63 1.50 1.85 1.62 0.07
BMI 63 18.03 41.52 29.93 5.30
Menarche 63 11 17 13.60 1.47
Regularity of menstrual cycle 63 21 30 28.44 1.39
Length of corpus of uterus (cm) 63 3.00 10.00 5.25 1.33
Thickness of endometrium (mm) 63 4.00 36.00 11.99 6.38
Menopause 63 36 56 50.00 3.98
Years in menopause 63 0.5 35.0 9.11 8.69
Table 5. T-test for equality of mean in group A and group B
Numerical variables T Degree of 
freedom
Significance Differences 
in mean
Age of patient 3.737 120 0.00** 5.68
Weight 0.390 120 0.698 0.9817
Height -0.588 120 0.558 -0.0065133
BMI 0.688 120 0.493 0.6248
Menarche -0.341 120 0.734 -0.0947
Regularity of menstrual cycle 1.450 120 0.150 0.66
Length of corpus of uterus (cm) 3.889 120 0.000** 1.1538
Thickness of endometrium (mm) 1.083 120 0.281 1.3626
Menopause 0.621 120 0.536 0.46
Years in menopause 2.670 120 0.009** 4.558
**significant statistical difference
Thickness of 
endometrium (mm)
1.083 120 0.281 1.3626
Menopause 0.621 120 0.536 0.46
Years in menopause 2.670 120 0.009** 4.558
**significant statistical difference
Figure 4. Box-whiskers relationship diagram of the display of the average age in the two 
groups
Figure  5. Box-whiskers relationship diagram of the display of the average length of 
uterus in the two groups
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Figure 4. Box-whiskers relationship diagram of the display of the average age in the two groups8
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bleeding (1). Due to decreased production of estrogen after menopause, 
the appearance of the endometrium is changed and it becomes atrophic 
and on ultrasound examination, it appears as a thin line that represents 
stratum basale (19). Histological examination indicates that thickness of 
endometrium rarely exceeds 3 mm in physiological conditions. In addition, 
it is not possible to visualize endometrium in 7% to 10% of women in post-
menopause that do not bleed from uterus (20). Numerous studies tried to 
define the threshold for thickness of endometrium by means of transvagi-
nal ultrasound, which could indicate the existence of pathological changes 
in the endometrium. Smith-Bindman et al. make the meta-analysis of 35 
studies and find that the sensitivity for detection of pathological changes 
on an endometrium is more than 92% if the endometrial thickness is 5 mm 
(21). A large multicentre study that included 1168 women with postmeno-
pausal bleeding and the thickness of an endometrium 4 mm or less was 
conducted in Norway; of these women, Karlsson et al. diagnosed 14 who 
had pathological changes such as hyperplasia and polyp of endometrium. 
However, there was no cancer diagnosed. If we took this value as a thresh-
old for appearance of pathological changes in an endometrium, the sen-
sitivity would range from 96%, specificity 68%, PPV 61%, NPV 97%, and 
overall accuracy was 78%. When the threshold was 5 mm, sensitivity was 
94%, specificity 78%, PPV 69%, NPV 96%, and overall accuracy was 84%. 
In an endometrium with thickness less than 5 mm, risk of appearance of 
pathological changes was 5.5% (22). Curcic established the threshold of 
endometrial thickness of 5 mm with sensitivity of 98%, specificity 44%, 
PPV 51%, NPV 98% for prediction of cancer and confirmed certainty for 
detection of endometrial cancer for this threshold (23).
In our study, average endometrial thickness of the examined women with 
postmenopausal bleeding was 12.66 mm. In the group with verified endo-
metrial cancer, average endometrial thickness was 13.36 mm while it was 
12 mm in the group with benign changes. Although there was obvious dif-
ference between average endometrial thicknesses, statistical significance 
was not confirmed. In addition, we did not determine that there was a sig-
nificant difference in endometrial thickness regardless whether the change 
was malignant or benign. Curcic et al. confirmed significantly thicker 
endometrium in women with endometrial cancer concerning the women 
with benign changes (23). The same author established the statistical 
significance for the length of uterus in longitudinal section in women with 
malignancy with regard to benign group. In our study, we found that the 
length of uterus in longitudinal section was statistically different in patients 
with endometrial cancer compared to those with benign changes.
If we measured only the endometrial thickness in the both groups of 
patients, we would not be able to diagnose the real cause of PMB. The 
mean measurements of an endometrium are pathologic in the both groups, 
and all of these women were definitely indicated for histopathological analy-
sis of the endometrium. The use of transvaginal ultrasound examination for 
diagnosis of pathological changes in endometrium is still the first diagnostic 
tool. Any thickness greater than 5 mm in the setting of postmenopausal 
bleeding or any endometrial heterogeneity or focal thickening seen at 
transvaginal US should be investigated . Therefore, there is no place to use 
it as a screening method in a general population. Langer et al. report that 
if the endometrial thickness is 5 mm or more, explorative curettage will be 
needed at half of those women, but only 10% of them would be diagnosed 
with age of women. Therefore, longer postmenopausal period increases 
the risk for developing malignant change in endometrium (12). In our 
study, we confirmed statistically significant difference in length of post-
menopausal period in women with malignant than in women with benign 
changes of endometrium.
Numerous studies report that obesity is important risk factor for develop-
ing of endometrial cancer (14-17). In our study, we did not confirm the 
difference in BMI between women with malignant and benign changes, 
since the total mean value for BMI for both groups is 30.32 and according 
to the classification of level of nutrition, all of them were obese. Based 
on that we can confirm that every endometrial change developed at the 
examined women, whether they are malignant or benign, depend of given 
risk factor, obesity.
Vermenlen, in his study, pointed to estrone as major estrogen for women 
in postmenopausal period, which is predominantly created by peripheral 
aromatization of circulating androstenedione (18). Incubation of adipose 
tissue in vitro using androstenedione and 19-hydroxsiandrostenedion as 
substrate showed conversion mostly to estrone. How is it going that pro-
duction of estrone is associated with obesity degree, therefore stimulation 
of endometrium should be identical in both groups.
Among women in the postmenopausal period, bleeding from the genital 
organs is the main sign to visit a gynecologist. Malignant change and 
endometrial cancer also lead to postmenopausal bleeding. Although in 
90% there is vaginal bleeding in endometrial cancer, cancer is cause of 
postmenopausal bleeding in 25% cases, so it is necessary to bear in 
mind other causes of bleeding from the genital organs. Gynecological 
examination is indispensable in order of distinguish the cause of 
Thickness of 
endometrium (mm)
1.083 120 0.281 1.3626
Menopause 0.621 120 0.536 0.46
Years in menopause 2.670 120 0.009** 4.558
**significant statistical difference
Figure 4. Box-whiskers relationship diagram of the display of the average age in the two 
groups
Figure  5. Box-whiskers relationship diagram of the display of the average length of 
uterus in the two groups
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Figure 5. Box-whiskers relationship diagram of the display of the average length of uterus in the two groups
Figure 6. Box-whiskers relationship diagram of the display of the average duration of postmenopausal period in 
the two groups
Figure 6. Box-whiskers relationship diagram of the display of the average duration of 
postmenopausal period in the two groups
DISCUSSION
Endometrial cancer is most often diagnosed tumor of female genital tract in developed 
countries (9). In developing countries as well as it is in our country there is rising tendency for 
incidence of this cancer (10, 11).
In 75% of cases, endometrial cancer appears in women in menopause so we can talk about 
cancer of older population. Incidence of endometrial cancer rises from 2/100 000 of women 
under 40 years old to 40-50/100 000 of women in sixth, seventh, and eight decade of life (12).
Average age of women with endometrial cancer in our study was 64.49 years and that is a
statistically significant difference from women with benign changes of endometrium with 
average age of 58.8 years. However, 25% of endometrial cancer appears in premenopausal 
period while 5% of diagnoses are established among women younger than 40 years (13). The 
risk for developing endometrial cancer is associated with age of women. Therefore, longer 
postmenopausal period increases the risk for developing malignant change in endometrium 
(12). In our study, we confirmed statistically significant difference in length of 
postmenopausal period in women with malignant than in women with benign changes of 
endometrium.
Numerous studies report that obesity is important risk factor for developing of endometrial 
cancer (14-17). In our study, we did not confirm the difference in BMI between women with 
malignant and benign changes, since the total mean value for BMI for both groups is 30.32
and according to the classification of level of nutrition, all of them were obese. Based on that 
we can confirm that every endometrial change developed at the examined women, whether 
they are malignant or benign, depend of given risk factor, obesity.
Vermenlen, in his study, pointed to estrone as major estrogen for women in postmenopausal 
period, which is predominantly created by peripheral aromatization of circulating 
androstenedione (18). Incubation of adipose tissue in vitro using androstenedione and 19-
hydroxsiandrostenedion as substrate showed conversion mostly to estrone. How is it going 
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as serious pathological endometrial change (24). Archer et al. diagnose 
one well-differentiated endometrial cancer of 801 asymptomatic postmeno-
pausal women who have had substitution hormonal therapy (25). Gronroos 
et al. presented the results of screening among 597 high-risk women of age 
between 45 and 69 years who had hypertension and/or diabetes. No cancer 
was diagnosed, but 6 atypical hyperplasias were diagnosed (26).
Gupta et al. have analyzed 57 studies in their meta-analysis and they 
determine the most frequent limit values of endometrial thickness is from 
4 to 5 mm; they also examined the accuracy of ultrasound as the only 
method in the detection of endometrial pathology. Their results indicate 
that the measurement of endometrium only has limits in prediction of 
hyperplasia or cancer, but it is very good test for excluding pathological 
changes of endometrium (27).
The problem in differential diagnosis of the PMB cause during standard 
vaginal ultrasound examination is to distinguish focal from diffuse 
changes and benign from malignant changes.
Today we use hysteroscopy and sonohysterography in distinguishing 
diffuse from focal changes (28-30).
Histopathological analysis of endometrial sample is the best method for 
establishing the diagnosis of endometrial cancer. Explorative curettage is 
not anymore a golden standard for getting the sample of endometrium; 
today, it is less invasive endometrial biopsy. If we use special aspirate 
biopters (Pipelle or Vabrata) possibility for complications during explor-
ative curettage are reduced. It is estimated that more than 50% curettages 
do not discover pathological changes of endometrium (31). Explorative 
curettage is associated with surgical complications including perforation 
in 0.6%-1.3%, bleeding in 0.4%, and infections in 0.3%-0.5% cases (32). 
Multiple studies show that the diagnostic curettage in diagnosis of irregu-
lar uterine bleeding is increasingly replaced by less invasive procedures 
such as endometrial biopsy or hysteroscopy, which are performed in 
outpatient conditions (30, 31, 33). In developed countries, curettage is 
a method of choice only if biopsy in outpatient facilities or direct hys-
teroscopy cannot be done. In the nowadays studies we can see that an 
endometrial biopsy is method of choice for diagnosis of premalignant 
and malignant endometrial condition; if there is focal endometrial lesion 
this method is not highly sensitive, unlike the hysteroscopy or sonohys-
terography (30-33).
CONCLUSION
Women with longer postmenopausal interval and PMB have higher risk for 
detection of endometrial cancer.
Endometrial thickness measured by transvaginal ultrasound is not sufficient 
parameter for differencing benign from malignant endometrial changes.
Patients with endometrial cancer have statistically significant longer uter-
ine corpus than patients with benign endometrial changes.
Body mass index (BMI) was not a significant risk factor for endometrial 
cancer. In the both groups obesity is diagnosed which indicates BMI as a 
risk factor for developing of pathological changes in endometrium which 
could causes clinical symptom, PMB.
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